AGÕæÈ˹ٷ½

STOCK TITAN
  1. Home
  2. Sec-filings
  3. LXEO
  4. [EFFECT] Lexeo Therapeutics, Inc. SEC Filing

[EFFECT] Lexeo Therapeutics, Inc. SEC Filing

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
EFFECT
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Notice of Effectiveness
Effectiveness Date: June 30, 2025 4:00 P.M.
Form: S-3
CIK: 0001907108
Company Name: Lexeo Therapeutics, Inc.
File Number: 333-288025

Source:

Stock LXEO logo
Lexeo Therapeutics Inc

NASDAQ:LXEO

LXEO Rankings

#3962 Ranked by Market Cap
N/A Ranked by Dividends

LXEO Latest News

Aug 14, 2025
Lexeo Therapeutics Reports Second Quarter 2025 Financial Results and Operational Highlights
Jul 7, 2025
Lexeo Therapeutics Announces FDA Breakthrough Therapy Designation for LX2006 in Friedreich Ataxia
Jun 24, 2025
Lexeo Therapeutics, Perceptive Xontogeny Venture Funds and venBio Partners Announce Partnership to Advance Novel Cardiac RNA Therapeutics
May 27, 2025
Lexeo Therapeutics Announces $80 Million Equity Financing to Further Advance Development of Transformative Genetic Medicines for Cardiovascular Diseases
May 12, 2025
Lexeo Therapeutics Reports First Quarter 2025 Financial Results and Operational Highlights

LXEO Latest SEC Filings

Aug 14, 2025
[SCHEDULE 13G/A] Lexeo Therapeutics, Inc. SEC Filing
Aug 14, 2025
[10-Q] Lexeo Therapeutics, Inc. Quarterly Earnings Report
Aug 14, 2025
[8-K] Lexeo Therapeutics, Inc. Reports Material Event
Aug 14, 2025
[SCHEDULE 13G] Lexeo Therapeutics, Inc. SEC Filing
Aug 7, 2025
[SCHEDULE 13G/A] Lexeo Therapeutics, Inc. SEC Filing

LXEO Stock Data

239.68M
28.32M
0.75%
121.47%
9.59%
Biotechnology
Biological Products, (no Disgnostic Substances)
United States
NEW YORK